Medtronic Reports Results of MiniMed 640G System in the SMILE Study for Reducing Hypoglycemia in Patients with Type 1 Diabetes


  • The SMILE study involves assessing of MiniMed 640G system with SmartGuard technology vs insulin pump therapy without continuous glucose monitoring (CGM) in 153 adults with T1D, prone to severe hypoglycemia for 6mos. across 16 centers
  • The SMILE study demonstrated a reduction in both biochemical and severe hypoglycemia (84%) without increasing HbA1c levels, improvement in Time in Range spent by patients using the MiniMed 640G system with SmartGuard Suspend before low
  • Medtronic’s SmartGuard technology imitates the function of the healthy pancreas with insulin delivery feature (suspend before low) when the glucose level is approaching to its lower limit, thus preventing hypoglycemic attacks

Click here to read full press release/ article | Ref: GlobeNewsWire | Image: Medtronics